Henlius Reports First Patient Dosing with HLX11 (biosimilar, pertuzumab) for HER2-Positive Metastatic Breast Cancer and Early Breast Cancer

 Henlius Reports First Patient Dosing with HLX11 (biosimilar, pertuzumab) for HER2-Positive Metastatic Breast Cancer and Early Breast Cancer

Henlius Reports First Patient Dosing with HLX11 (biosimilar, pertuzumab) for HER2-Positive Metastatic Breast Cancer and Early Breast Cancer

Shots: 

  • The company has reported the first patient dosing in P-l study assessing the safety, tolerability, and immunogenicity of HLX11 vs US-, EU- and China-sourced reference pertuzumab in healthy Chinese male
  • The 1EPs of the study is to compare the PK b/w HLX11 and the three different sourced reference drugs head-to-head while the 2EPs is to evaluate the safety, tolerability, and immunogenicity of HLX11 and the reference drug, further describing the PK profile
  • HLX11 can be potentially used for the treatment of HER2-positive mBC & eBC. Additionally, the study demonstrated that combining pertuzumab with trastuzumab and CT can decrease the risk of recurrence or death for HER2+ BC

Click here ­to­ read full press release/ article | Ref: Henlius | Image: Henlius

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post